We are pioneering a new class of medicine we call endobody vaccines that are fully synthetic and train the body to safely and efficiently treat and prevent neurological disease.
We are not afraid to be brave and tackle the seemingly impossible. We are committed to transforming the lives of all patients and families affected by Alzheimer’s, Parkinson’s, CTE and other neurological diseases.
We envision a world where neurodegenerative diseases are prophylactically eradicated.
By The Numbers
80 years ago, it was polio. Today, our epidemic is Alzheimer’s.
CHANCE YOU WILL HAVE ALZHEIMER’S
IF OVER 85 YEARS OLD
ANNUAL COST TO THE WORLD
Just as science brought us a vaccine against polio and virtually eradicated the disease worldwide, we are working to develop vaccines to treat and ultimately prevent Alzheimer’s and other neurological diseases.
We aren’t your average vaccine company.
We have built a robust translational platform to rapidly design and develop targeted immunotherapeutics based on the industry’s leading endobody vaccine technology. After two decades of research and over 3 billion doses commercialized on other indications, we are now developing the world’s most advanced active vaccine against Alzheimer’s.
April 4, 2019 -
Mei Mei Hu, United Neuroscience CEO, and Dr. Paul Alan Cox, Brain Chemistry Labs CEO, discuss their experience and research with Alzheimer’s and their approach to curing the disease.Read More
March 28, 2019 -
United Neuroscience (UNS), a clinical-stage biotech company pioneering a new class of medicine to treat and prevent brain disorders, today announced an upcoming presentation on Phase IIa results of its lead clinical product, UB-311, at the 14th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) in Lisbon, Portugal, from MarchRead More